Michigan Herbal Remedies 2/4/16
| || |
Department of Health and Human Services
|Public Health Service|
Food and Drug Administration
| || |
February 4, 2016
VIA OVERNIGHT DELIVERY
RETURN RECEIPT REQUESTED
Michigan Herbal Remedies, LLC (aka MHR LLC)
d/b/a Tasty Hemp Oil
d/b/a US Hemp Wholesale
d/b/a Alternate Vape
6411 Bella Vista Drive
Rockford, MI 49341
Dear Jeff Gallagher:
This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the internet addresses www.michiganherbalremedies.com, www.tastyhempoil.com, www.ushempwholesale.com, and www.alternatevape.com in January 2016, and has determined that you take orders there for the products “Bluebird Botanicals Bulletproof CBD Blend,” “US Hemp Wholesale 25% CBD Hemp Oil Supplement” (aka “Gold Label CBD Hemp Oil”), “Plus CBD Oil,” “Endoca Hemp Oil,” “Tasty Hemp Oil Tasty Drops,” “Tasty Vape Just Peachy” and “Alternate Vape Luv-A-Bull,” which you claim to contain cannabidiol (CBD). FDA also reviewed your social media websites at https://twitter.com/michiganherbal, https://twitter.com/tastyhempoil, https://twitter.com/ushempwholesale, https://twitter.com/alternatevape, and https://www.pinterest.com/MichiganHerbal/. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.
Although you market “Bluebird Botanicals Bulletproof CBD Blend,” “US Hemp Wholesale 25% CBD Hemp Oil Supplement” (aka “Gold Label CBD Hemp Oil”), “Plus CBD Oil,” “Endoca Hemp Oil,” and “Tasty Hemp Oil Tasty Drops” as dietary supplements, FDA has concluded based on available evidence that CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the Act [21 U.S.C. § 321(ff)(3)(B)(ii)]. Under that provision, if an article (such as CBD) has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD.
The existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex
. FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under FDA’s regulations (21 CFR § 312.2), unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the Act. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the Act, but you may present FDA with any evidence that has bearing on this issue.
Examples of claims observed on your websites that establish the intended use of your products include, but may not be limited to, the following:
On the website www.michiganherbalremedies.com:
- Gold Label Hemp Oil
- “Studies show CBD is a natural anti-inflammatory with great potential towards issues including anti-anxiety, anti-pain, anti-psychosis, anti-spasm, and more.”
- Blog post titled “CBD Neuroprotective Effects Shown in Studies”
- “CBD . . . could have many properties including anti-inflammatory, anti-psychotic, anti-tumor, and more.”
- Blog post titled “Research on CBD Anti Inflammatory Effects”
- “Research suggests that cannabidiol may be a useful tool for reducing systemic inflammation, application towards multiple sclerosis, and implications from colorectal cancer.”
- “CBD provided long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis . . ..”
On the website www.tastyhempoil.com:
- Blog post titled “Government Funded Cannabis Cancer Research”
- “CBD, when used with radiation, increased cancer-killing effects of the radiation.”
- Blog post titled “Study: CBD Neuroprotective Effects in Mice with Cerebral Malaria”
- “[C]annabidiol (CBD) showed neuroprotective effects in models with cerebral malaria.”
- Blog post titled “Hemp-derived CBD May Help Sufferers of Sleep Disorders”
- “Parkinson’s Disease sufferers experience various sleep disorders . . . [t]hese disorders are usually challenging and very difficult to treat. However, CBD has been shown to greatly reduce such symptoms in patients making them sleep much better.”
- Blog post titled “CBD Antipsychotic Antitumor and Anti-inflammatory Research”
- “CBD may reduce symptoms of schizophrenia . . . .”
On the website www.ushempwholesale.com:
- Frequently Asked Questions under “How much CBD do I need?”
- “Here are some general recommendations for a person weighing about 150 pounds, based on various research studies on CBD oil, as well as our own customers’ feedback and success stories . . . [u]p to 90 drops of CBD oil (or the equivalent of up to 3 ml) for any other serious health condition including diabetes, cancer, MS and others . . ..”
- Blog post titled “CBD Antipsychotic Properties of Cannabidiol”
- “CBD is as effective as traditional medications in treating schizophrenia. This latest research supports earlier theories that CBD could be effective as an antipsychotic medication . . . .”
- Blog post titled “Cannabidiol CBD Antidepressant Effects”
- “CBD to have the ability to help combat anxiety and depression disorders . . . and treat psychosis disorders.”
On the website www.alternatevape.com:
- Silver Blend: Luv-A-Bull CBD Vape Oil (25-300mg)
- “CBD has been studied throughout the world for its potential anti-anxiety and anti-inflammatory properties, among other things.”
Examples of claims observed on your social media accounts that establish the intended use of your products include, but may not be limited to, the following:
- August 11th 2015 posting – “Study says CBD helps broken bones heal faster . . .”
- March 31st 2015 posting – “Cannabidiol Breakthrough in #Cancer Treatment . . .”
- February 22nd 2015 posting – “CBD . . . Cannabidiol . . . REDUCE SPASTICITY . . . ATTACK CANCER TUMORS . . .”
- June 10th 2015 posting – “Study: Cannabidiol Protects Against Cocaine-Induced Toxicity . . .”
- January 26th 2015 posting – “THE FUTURE OF MEDICINE – ALL IN 1 PLANT #cbd . . . Antibacterial . . . Inhibits cancer cell growth . . .”
- “[P]otential cannabidiol Parkinson’s treatments… a compound found in industrial hemp may help in managing symptoms of Parkinson’s disease . . .”
- “Cannabidiol PTSD – Scientific studies performed in clinical settings have confirmed the benefits CBD can provide to those with PTSD.”
- “Cannabidiol (CBD): Fighting Inflammation & Aggressive Forms of Cancer . . .”
Your products “Bluebird Botanicals Bulletproof CBD Blend,” “US Hemp Wholesale 25% CBD Hemp Oil Supplement” (aka “Gold Label CBD Hemp Oil”), “Plus CBD Oil,” “Endoca Hemp Oil,” “Tasty Hemp Oil Tasty Drops,” “Tasty Vape Just Peachy” and “Alternate Vape Luv-A-Bull” are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.
A drug is misbranded under 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR § 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Your products “Bluebird Botanicals Bulletproof CBD Blend,” “US Hemp Wholesale 25% CBD Hemp Oil Supplement” (aka “Gold Label CBD Hemp Oil”), “Plus CBD Oil,” “Endoca Hemp Oil,” “Tasty Hemp Oil Tasty Drops,” “Tasty Vape Just Peachy” and “Alternate Vape Luv-A-Bull” are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Bluebird Botanicals Bulletproof CBD Blend,” “US Hemp Wholesale 25% CBD Hemp Oil Supplement” (aka “Gold Label CBD Hemp Oil”), “Plus CBD Oil,” “Endoca Hemp Oil,” “Tasty Hemp Oil Tasty Drops,” “Tasty Vape Just Peachy” and “Alternate Vape Luv-A-Bull” fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].
The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products and their labeling. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations.
You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to:
U.S. Food and Drug Administration
10903 New Hampshire Avenue, WO51
Silver Spring, MD 20993-0002
Ilisa Bernstein, Pharm.D., J.D.
Office of Compliance
Center for Drug Evaluation and Research
 See “Sativex Commences US Phase II/III Clinical Trial in Cancer Pain,” available at http://www.gwpharm.co.uk/Commences%20US%20Phase%20IIIII%20Clinical%20Trial.aspx and “GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome,” available at http://www.gwpharm.com/GW%20Pharmaceuticals%20Receives%20Investigational%20New%20Drug%20IND%20from%20FDA%20for%20Phase%2023%20Clinical%20Trial%20of%20Epidiolex%20in%20the%20Treatment%20of%20Dravet%20Syndrome.aspx.